cemiplimab,e-602
regeneron,palleon pharma,sanofi
['e-602', 'glimmer-01']
today at #aacr23 we announced initial results from the phase 1 glimmer-01 trial of our lead oncology program, e-602. results demonstrated proof of mechanism for e-602, as well as dose dependent desialylation and dose dependent immune system activation. read about these results in 
Clinical-stage biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases